Impact of myelodysplasia-related and additional gene mutations in intensively treated patients with <em>NPM1</em>-mutated AML

This study aimed to evaluate the impact of the myelodysplasia-related gene (MRG) as well as additional gene mutations on outcomes in intensively treated patients with NPM1-mutated (NPM1 ^(mut)) AML. Targeted DNA sequencing of 263 genes was performed in 568 NPM1 ^(mut) AML patients (median age: 59 years) entered into the prospective AMLSG 09-09 treatment trial. Most commonly co-mutated genes were DNMT3A (49.8%), FLT3-TKD (25.9%), PTPN11 (24.8%), NRAS (22.7%), TET2 (21.7%), IDH2 (21.3%), …